Sagimet Biosciences (NASDAQ:SGMT) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.36) by 8.33 percent. This is a 41.07 percent increase over losses of $(0.56) per share from the same period last year.